# Pascal Soriot

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/pascal-soriot
Canonical HTML page: https://getyourbrief.com/entity/pascal-soriot

## Recent coverage (9 stories, network-wide)

### £300bn AstraZeneca-BMS Merger Faces Antitrust Firestorm Under Trump
2026-08-03 09:57:14 · Sector: legal · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The proposed mega-merger would immediately trigger intense antitrust reviews in the US, EU, and UK, testing the limits of Trump-era competition enforcement in the pharmaceutical sector. Significant divestitures and political pushback are likely, with a real risk of deal collapse.
Full story: https://getlegalbrief.com/story/astrazeneca-bms-merger-antitrust-300bn

### AstraZeneca-BMS £300bn Merger Could Reshape Global Drug Access and Pricing
2026-08-03 09:57:07 · Sector: health · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The potential combination of two pharmaceutical powerhouses would concentrate ownership of critical cardiovascular and oncology treatments, raising concerns about pricing power, NHS supply chains, and worldwide health equity.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-healthcare-impact

### AZN Shares Crash 6.1% as £300bn Merger Talks Spook Investors
2026-08-03 09:57:00 · Sector: finance · Sentiment: Neutral · Impact: 9/10 · Sources: 4

AstraZeneca shares plummeted in London trading after reports of merger talks with Bristol Myers Squibb, as the market priced in execution risk, regulatory peril, and potential overpayment for a deal that would create a £300bn giant.
Full story: https://getfinancebrief.com/story/astrazeneca-bms-merger-stock-market-impact

### AstraZeneca and BMS in Talks for £300bn Biotech Consolidation Play
2026-08-03 09:56:53 · Sector: bio · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth.
Full story: https://getbiobrief.com/story/astrazeneca-bms-biotech-merger-300bn

### AZN-BMS $400B Talks: What It Means for Drug Prices and Access
2026-08-02 23:37:50 · Sector: health · Sentiment: Neutral · Impact: 9/10 · Sources: 2

A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-pricing-access

### AstraZeneca, BMS $400B Merger Talk Sparks Pharma M&A Frenzy
2026-08-02 23:37:40 · Sector: finance · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
Full story: https://getfinancebrief.com/story/astrazeneca-bms-400b-merger-talks-markets

### AstraZeneca, BMS Eye $400B Union to Build Cancer Powerhouse
2026-08-02 23:37:29 · Sector: bio · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Full story: https://getbiobrief.com/story/astrazeneca-bms-oncology-pipeline-merger

### AstraZeneca CEO Pascal Soriot Receives £17.7M Pay Package for 2025
2026-02-24 20:14:28 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

AstraZeneca CEO Pascal Soriot's total compensation for 2025 reached £17.7 million, driven by significant performance-linked bonuses. The payout reinforces Soriot's position as one of the highest-paid executives in the FTSE 100 as the company pursues an ambitious $80 billion revenue target by 2030.
Full story: https://getbiobrief.com/story/astrazeneca-pascal-soriot-pay-2025

### AstraZeneca CEO Pascal Soriot Nets £17.7M in 2025 Pay and Bonuses
2026-02-24 20:13:54 · Sector: hr · Sentiment: Neutral · Impact: 5/10 · Sources: 3

AstraZeneca CEO Pascal Soriot’s total remuneration for 2025 reached £17.7 million, driven by strong corporate performance and long-term incentives. The payout highlights the ongoing tension between UK executive pay standards and the global competition for pharmaceutical leadership talent.
Full story: https://gethrbrief.com/story/astrazeneca-ceo-pascal-soriot-2025-compensation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.